Drug intelligence / Profile preview

BSEM-135

Development stage: Preclinical
Lead developer: Nesvik Pharmaceuticals
Modality: Small Molecules

Overview

**BSEM-135** is a reformulated drug candidate acquired by BioStem Technologies (BSEM) through its subsidiary Nesvik Pharmaceuticals for the treatment of **hypertension**. It is one of four drugs (BSEM-120, BSEM-125, BSEM-130, BSEM-135) identified for reformulation to improve availability and delivery, developed at Nesvik's FDA-registered facility. Limited public data exists on its specific mechanism of action, active ingredients, or clinical progress, suggesting it is in early reformulation stages without disclosed trials or approvals.[4][7]

Beyond the preview

Go deeper on BSEM-135.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSEM-135.

Explore the full profile